Beverly Incledon

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Part of Eli Lilly & Co., Eli Lilly Canada, Inc. is a healthcare leader that focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. The private company is based in Scarborough, Canada. Established in 1938, the Canadian company collaborates with scientists to produce innovative medicines that make life better for people around the world. The company's mission is to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to communities through philanthropy and volunteerism.

Pacgen Life Science Corp. is a life science technology company, which engages in the development and commercialization of biomedical products and services. It specializes in the operation of global commercial platform to market and distribute consumer health products developed by small business enterprises. The company focuses on oral care and skin care commercial rights. Pacgen Life Science was founded by Fred Huang and Chung Yu Wang on April 23, 2004 and is headquartered in Vancouver, Canada.

Concept 2 Clinic, Inc. operates as an executive research and development management company that specializes in pharmaceutical and biotechnology sectors. Its services include financial, opportunity assessment, pre-clinical and CMC. The company is headquartered in Markham, Canada.

Part of Ironshore Therapeutics, Inc., Ironshore Pharmaceutical & Development, Inc. develops novel therapeutics using its proprietary controlled-release drug-delivery technology. The private company is based in Camana Bay, Cayman Islands. Our lead products are developed using a unique and beneficial delayed-release and extended-release delivery to a specifically targeted area. Ironshore is a fully Caymanian integrated pharmaceutical company with experience developing and commercializing first-in-class therapeutic products. JORNAY PM is a first-in-class product indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. The company is committed to the development and commercialization of first-in-class treatment options to improve the lives of patients and caregivers. The CEO of the company is David Gordon MacLeod Lickrish.